These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical prevention of coronary heart disease through cholesterol-lowering therapy. Grundy SM Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799 [No Abstract] [Full Text] [Related]
3. Statin therapy for prevention of coronary artery disease with average cholesterol levels. Gambhir DS Indian Heart J; 1999; 51(1):19-20, 105. PubMed ID: 10327772 [No Abstract] [Full Text] [Related]
4. Clinical implications of clinical studies: can we compare different subgroups defined a posteriori? Vohnout B Eur Heart J; 2001 May; 22(9):798. PubMed ID: 11350113 [No Abstract] [Full Text] [Related]
5. A need to redefine the consensus on the use of statins in coronary heart disease prevention. Fruchart JC Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008 [No Abstract] [Full Text] [Related]
6. Regression of coronary artery disease as a result of intensive lipid-lowering therapy. N Engl J Med; 1991 Apr; 324(16):1133-5. PubMed ID: 2008188 [No Abstract] [Full Text] [Related]
7. Why do coronary patients gain a clinical benefit from polyunsaturated fatty acids? Rubba P Nutr Metab Cardiovasc Dis; 2000 Apr; 10(2):55-6. PubMed ID: 10919168 [No Abstract] [Full Text] [Related]
8. A clinical focus on statins. Auer J; Eber B Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol lowering drugs. Amarasingham R N Z Med J; 1990 Mar; 103(886):138. PubMed ID: 2181355 [No Abstract] [Full Text] [Related]
15. What do the statin trials tell us? Waters DD Am J Manag Care; 2001 May; 7(5 Suppl):S138-43. PubMed ID: 11383375 [TBL] [Abstract][Full Text] [Related]
16. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high]. MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408 [No Abstract] [Full Text] [Related]
17. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Preiss D; Sattar N Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719 [TBL] [Abstract][Full Text] [Related]
18. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1329-30. PubMed ID: 15297284 [No Abstract] [Full Text] [Related]
19. Cholesterol lowering, sudden cardiac death and mortality. de Lorgeril M; Salen P Scand Cardiovasc J; 2008 Aug; 42(4):264-7. PubMed ID: 18615354 [TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair? Frishman WH; Barkowski RS Am J Med; 2008 Aug; 121(8):644-6. PubMed ID: 18691473 [No Abstract] [Full Text] [Related] [Next] [New Search]